Supplementary Figure 1B.
BFA and GCA disperse the medial-Golgi marker giantin to a partially punctate pattern adjacent to ERES. Vero cells were treated with BFA (10 μg/ml) or GCA (10 μM) for 60 mins then fixed and labeled with antibodies against giantin (red) or Sec31 (green). Both compounds cause giantin redistribution into a hazy and punctate pattern. Giantin-positive punctate structures are closely approximated to Sec31-labeled ERES. White scale bars = 10 μm. Yellow scale bars = 5 μm. GCA does not affect microtubular or actin cytoskeletons. (a) Vero cells were treated for 30 min at 37ºC with DMSO, GCA, or nocodazole at the indicated concentrations prior to fixation and immunostaining, as described in Supplemental Methods. At 10 µM, GCA had no observable effects on microtubules, while nocodazole, an inhibitor of microtubule polymerization, produced drastic morphological effects. (b) Vero cells were treated with DMSO, GCA, or cytochalasin B at the indicated concentrations and developed for immunofluorescence, as in (a). GCA showed no effects on actin microfilaments compared to DMSO-treated cells, while the actindepolymerizing agent cytochalasin B induced significant changes to actin morphology. GCA does not affect transport through recycling endosomes. (a) GCA treatment maintains endocytic transport to recycling endosomes. Vero cells were treated for 15 min with DMSO (control; 0.5% v/v) or GCA (10 µM), then incubated with AlexaFluor 594-labeled CtxB (1 μg/mL) and 488-labeled Tfn (1 μg/mL) for 1 h at 4°C in serum-free medium prior to shifting cells to 19°C for an additional hour. Cells were then fixed and developed for immunofluorescence. GCA, similar to control cells, did not affect CtxB trafficking to a juxtanuclear, Tfn-positive recycling endosome compartment. Blue, nuclei. (b) GCA treatment does not affect the kinetics of transferrin recycling. Vero cells were left untreated or were treated with GCA for 1 h. Cells were allowed to internalize AlexaFluor-488 labeled transferrin for 60 min. Fresh media containing quenching anti-AlexaFluor-488 antibodies were added, and at various times the cells were harvested and fixed (see Supplementary Methods). Each time point was performed in triplicate, and the mean and standard deviation of each is presented. All data were fitted by nonlinear regression assuming one phase decay, and halflives (in min; inset) were calculated using GraphPad Prism. CtxB, cholera toxin B subunit; Tfn, transferrin. White scale bar = 20 μm. Supplemental Figure 8B . Expression of GBF1-ML but not GBF1-loop mutants results in resistance to the effects of BFA on Golgi morphology. Vero cells were transiently trasfected with GBF1-WT, or a GBF1-R843A, GBF1-K844A, GBF1-Q845A, or GBF1-N846A. Thirty six hours later the cells were treated for 60 mins with GCA (10μM) then fixed and labeled with anti-HA epitope (GBF1; red) or giantin (green). Cells expressing GBF1-R843A, GBF1-Q845A, and GBF1-N846A are resistant to the effects of GCA on Golgi morphology, whereas cells expressing GBF1-WT and GBF1-K844A are only partially protected. White asterix mark the partially protected cells. White scale bar = 20 μm. Figure 10 . Expression of GBF1-ML or GBF1-loop mutants results in resistance of the effects of GCA on ts VSVG-GFP transport. Vero cells were co-transfected with tsVSVG-GFP and either GBF1-WT or a GBF1-mutant. One day after transfection the cells were incubated for 12 hrs at 42 o C to arrest VSVG-GFP in the endoplasmic reticulum. The cells were treated with GCA (10 μM) for 30 mins then shifted to 32 o C and incubated 4 hrs. The cells were then fixed and labeled with anti-HA (red) antibodies. Whereas expression of GBF1-WT fails to rescue VSVG-GFP transport in the presence of GCA, GBF1-ML and the GBF1-loop mutants are resistant to the effects of GCA. White scale bars = 20 μm.
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VSV-G Supplementary Methods GCA synthesis. Dicyclopentadiene (100 mL) was placed in a round-bottomed flask equipped with a magnetic stirbar and a column fitted with a distillation head through which cold water was circulated. The contents of the flask were slowly heated with stirring to 160 0 C in oil bath, and 60 mL of cyclopentadiene was collected in a receiver 1 . Site-Directed Mutagenesis. GBF1-HA was generated by PCR using primers GBF1-HA (5'-GCCGCGCTAGCCTGAGGCATAGTCAGGCACGTCATAAGGATAGCCGTTG ACTTCAGAGGTGGGAATAGGGTCTGTAG-3') and the upstream GBF1 primer (5'-GACAGGTTTGCCAAGATGGTGGATAAGAATATTTACATC-3'). The resulting PCR product was cloned into pcDNA3.1D/V5-His-TOPO (Invitrogen) under control of the cytomegalovirus (CMV) promoter. The insert was sequenced to ensure its fidelity.
The GBF1 mutants were generated using the QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene). Mutagenic primers were E794K sense (5'-GCCTTCCGTTTGCCCGGGAAGGCACCAGTTATTCACAGGTTGC-3'), E794K
antisense (5'-GCAACCTGTGAATAACTGGTGCCTTCCCGGGCAAACGGAAGGC-3'), M832L sense (5'-GGCCTATGCTGTCATCTTGCTTAATACTGACCAGC-3'), and M832L antisense (5'-GCTGGTCAGTATTAAGCAAGATGACAGCATAGGCC-3').
Mutant clones were sequenced to ensure their fidelity. Transferrin Recycling Assay. Transferrin (Tf) recycling was analyzed by modification of a previously published assay for recycling of low density lipoprotein related protein 2 .
2 x 10 5 Vero cells were seeded per well in seven 12-well dishes. The following day, media was removed and replaced with 500 μl serum-free media containing Tf-488
(Invitrogen) at 5 μg/ml and either no compound or B06 (10 μM). The samples were incubated at room temperature for 60 min to allow Tf transport to recycling endosomes.
Cells were washed twice with 1 ml PBS, then overlaid with 400 μl media containing 10%
FCS, anti-AlexaFluor-488 antibody (Invitrogen) at 15 μg/ml, and either no compound, BFA (10 μg/ml), or B06 (10 μM). Τ=0 min samples were maintained at room temperature to prevent recycling. The remaining samples were incubated at 37ºC and at various times ranging from 10 to 60 min. Media was removed, and 500 μl prewarmed The VHS and GAT domains from human GGA3 were amplified from a human cDNA library using primers 5-GGCCGAATTCATGGCGGAGGCGGAAGGGGA-AAGC-3' and 5'-CCGGCTCGAGTCAGTCAGGCAGGGTTAAGGTAGCCACCTCG-3' The resulting product was initially cloned into plasmid pcDNA3.1/V5/His and sequenced to ensure its fidelity. The product was then released by digestion with EcoRI and XhoI and ligated into similarly digested plasmid pGEX-6p1. Expression of the recombinant GGA3-GST protein was induced by the addition of IPTG and the protein purified from crude bacterial lysates on a GSTrap column (Pharmacia). The protein was dialyzed into 50 mM Tris pH 7.5 plus 100 mM NaCl and used in Arf1 pulldown assays using the protocol of Santy and Casanova 3 , with the following modifications.
expressing Arf1-V5 alone, or co-transduced with virus expressing Arf1-V5 and virus expressing GBF1-ML-HA. After overnight incubation, the cells were washed, trypsinized, and seeded into three 25 cm3 flasks each. The following day, monolayers were treated at 37 o C for 45 min with media alone, or media containing BFA (10 μg/ml) or GCA (10 μM). The cells were then washed with cold PBS and scraped into 1 ml lysis buffer (50 mM Tris pH 7.6, 100 mM NaCl, 2 mM MgCl2, 1 % SDS, 1 % Triton X-100, and 10% glycerol,). To each sample was added 48 μg of GGA-GST bound to 30 μl of glutathione agarose (Pierce Chemical Company). The samples were incubated rocking at 4 o C for 30 mins, then the beads pelleted and washed three times with cold GGA wash buffer (50 mM Tris pH 7.6, 100 mM NaCl, 2 mM MgCl2, 1% NP-40, and 10% glycerol).
SDS-PAGE loading buffer was added, the samples were boiled, and equal aliquots separated by SDS-PAGE. Arf1 was detected by Western blot using anti-V5 antibody were then treated with cycloheximide (100 μg/ml) to prevent de novo protein synthesis and either no compound, GCA (10 μM), or brefeldin A (10 μg/ml) then transferred to o C. Cells were fixed following various incubation times at 32°C. Fixation, permeabilization, staining, and imaging were performed as described for immunofluorescence experiments.
NPY-GFP secretion assay. The NPY-GFP assay was similar to that previously reported 4 , with slight modifications. Briefly, 10 6 Vero cells were transduced overnight at 37ºC in 5% CO 2 with pAD-NPY-GFP. Cells were then washed, trypsinized, and seeded into a 96-well plate (~1 x 10 4 cells/well). The next day, the cells were washed once with PBS then incubated at 37ºC with media containing DMSO, BFA (10 μg/ml), or GCA (10 μM). Supernatants were collected at various times thereafter. GFP quantitation was performed by ELISA using anti-GFP coated plates (Pierce) and rabbit anti-GFP in solution. Mean absorbance for control wells containing DMEM alone were subtracted from sample wells. Calculation of GFP concentration was performed by comparison to a recombinant GFP (rGFP; Boehring Manneheim) standard curve.
StxB-SS-His
Sulfation. An StxB construct containing a tandem of carboxy-terminal sulfation sites and a histidine tag for purification (StxB-SS-His) has been described 4 .
Vero cells seeded in a 6-well plate (1 x 10 6 cells/well) were washed three times in serumfree DMEM lacking sulfate (Washington University Tissue Culture Support Center), and then incubated in sulfate-free medium for 3.5 h at 37ºC. After treatment with DMSO (0.5% v/v), BFA (10 μg/ml) or GCA (10 μM) 30 min at 37ºC, media was replaced with sulfate-free media containing these compounds plus StxB-SS-His (1 mg/ml) and 1 mCi/ml [ 35 S]O 4 for 3 h at 37ºC. Wells were washed with cold PBS (pH 7.4) and lysed with PBS containing 1% Triton X-100. Lysates were added to 40 µl Ni-NTA Superflow beads (Qiagen) and rotated at 4ºC overnight. Beads were washed once with PBS containing 1% Triton X-100 and twice with PBS, then resuspended in imidazole (1.5 M in PBS). Eluates were resolved on a 10-20% Tris-HCl denaturing gel, treated with EnHance reagent (DuPont), dried and exposed to film. Band intensity was determined using ImageJ software.
Statistical analysis. All statistical analyses were performed by GraphPad Prism 5.
Toxin concentrations were log transformed prior to curve fitting and statistical analyses.
Toxin-response curves were generated by nonlinear regression (least-squares fit) to correspond to the observed data, and toxin IC 50 (the concentration of toxin required to reduce protein synthesis by half) and compound IC 50 (the concentration of compound required to reduce Stx activity by half) values were calculated using the fitted curves.
For the compound-response curves, the GCA concentration varied while keeping the concentration of Stx (1 ng/ml) constant. For the toxin-response curves, the toxin concentration varied, while the concentration of DMSO or GCA was kept constant.
Toxin IC 50 values were compared using the extra sum-of-squares F test applied to the best-fit curves for the data. Differences between toxin IC 50 values were considered highly statistically significant for p≤0.01. For assessment of Arf1-GTP levels, values were considered statistically significantly different for p≤0.05 (*), whereas ns denotes a non-significant difference (p>0.05).
